Article
Author: Jaakola, Veli-Pekka ; Van Roy, Maarten ; Samyn, Noor ; Perneel, Lisa ; Busch, Andreas ; Skieterska, Kamila ; Debaere, Melanie ; Laeremans, Toon ; Menet, Christel ; De Cesco, Stéphane ; Virmani, Richa ; Liang, Yi-Lynn ; Vantieghem, Charlotte ; Staelens, Stephanie ; Loeys, Nicolas ; Dekeyzer, Lies ; Triest, Sarah ; Masiulis, Simonas ; Fontaine, Thomas ; Martini, Murielle ; Sands, Zara ; Barroco, Rosa
The melanocortin receptor 4 (MC4R) belongs to the melanocortin receptor family of G-protein coupled receptors and is a key switch in the leptin-melanocortin molecular axis that controls hunger and satiety. Brain-produced hormones such as α-melanocyte-stimulating hormone (agonist) and agouti-related peptide (inverse agonist) regulate the molecular communication of the MC4R axis but are promiscuous for melanocortin receptor subtypes and induce a wide array of biological effects. Here, we use a chimeric construct of conformation-selective, nanobody-based binding domain (a ConfoBody Cb80) and active state-stabilized MC4R-β2AR hybrid for efficient de novo discovery of a sequence diverse panel of MC4R-specific, potent and full agonistic nanobodies. We solve the active state MC4R structure in complex with the full agonistic nanobody pN162 at 3.4 Å resolution. The structure shows a distinct interaction with pN162 binding deeply in the orthosteric pocket. MC4R peptide agonists, such as the marketed setmelanotide, lack receptor selectivity and show off-target effects. In contrast, the agonistic nanobody is highly specific and hence can be a more suitable agent for anti-obesity therapeutic intervention via MC4R.